多西他赛联合塞替派治疗中晚期非小细胞肺癌的临床观察  

A clinical trial of docetaxel plus thiotepa in the treatment of advaced non-small cell lung cancer

作　　者：罗荣[1] 杨松涛[1] 吴进[1] 陈晶[2] 

机构地区：[1]四川大学华西第四医院内3科,四川成都610041 [2]四川省肿瘤医院内科,四川成都610041

出　　处：《四川医学》2013年第5期617-619,共3页Sichuan Medical Journal

摘　　要：目的探讨多西他赛联合塞替派治疗中晚期非小细胞肺癌的疗效及不良反应。方法中晚期非小细胞肺癌86例,随机分为两组,应用多西他赛联合塞替派方案(A组)(多西他赛35mg/m2d1,8,塞替派60mg/m2d1,21d为1疗程),多西他赛联合顺铂方案(B组)(多西他赛35mg/m2d1,8,顺铂80mg/m2d1,21d为1疗程)化疗2个疗程,评价其效果。结果 A组和B组治疗效果分别为:两组均无完全缓解(CR),部分缓解(PR)25.58%vs 20.93%,稳定(SD)53.49%vs48.83%,进展(PD)20.93%vs 39.70%。P值均>0.05,差异无统计学意义;最常见不良反应为骨髓抑制、胃肠道反应(恶心,呕吐)、肝脏损害转氨酶升高,手足综合征程度较轻。两组患者不良反应0～Ⅱ°和Ⅲ°～Ⅳ°比较,差异无统计学意义(P>0.05)。结论多西他赛联合塞替派方案治疗中晚期非小细胞肺癌有一定的近期疗效,不良反应可耐受,可以作为经济有效的化疗方案。Objective To evaluate the efficacy and safety of docetaxel and thiotepa in the treatment of advaced non-small cell lung cancer.Methods 86 patients of dvaced non-small cell lung cancer were randomized to give in travenous docetaxel 35 mg/m2on day 1 and 8 plus thiotepa 60mg/m2on day 1（groupA）;and in travenous docetaxel 35mg/m2on day 1 and 8 plus cisplatin 80mg/m2on day 1（groupA）;every 3 weeks,at least 2 cycles applied.Results Docetaxel thiotepa group（43cases） and docetaxel combined with cisplatin group（43cases） were evaluated for their clinical responses,which showed that 25.58% vs 20.93% for partial remission;53.49% vs 48.83% for stable diseases;20.93% vs 39.70% for progressive diseases.P0.05,and the two groups showed no difference.There was no significant difference in adverse reactions between the two groups（P0.05）.Conclusion Combination of docetaxel and thiotepa in the treatment of advaced non-small cell lung cancer has some curative effect and adverse reactions can be tolerated.It can be used as an economical and effective plan.

关 键 词：非小细胞肺癌 多西他赛 塞替派 

分 类 号：R734.2[医药卫生—肿瘤]